Payment overview · 2025
General Payments
2 reported records · 2 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Internal Medicine · BALTIMORE, MD · NPI 1124530316
Verified facts
CMS Open Payments records show Alex M Geiger, MD, MPH received $55.76 in general payments during 2025 across 2 reported records.
ViiV Healthcare Company accounted for 50.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
2 reported records · 2 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $28.04 | 50.3% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $27.72 | 49.7% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $28.04 | 1 |
| Long term medical supply or device loan | $27.72 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $28.04 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - ELI 280 Normalized: hillrom eli 280 |
Device | Baxter Healthcare | $27.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 202 | 34 |
| Atorvastatin Calcium | Atorvastatin Calcium | 201 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 110 | 28 |
| Lisinopril | Lisinopril | 107 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 32 |
| Losartan Potassium | Losartan Potassium | 81 | 21 |
| Gabapentin | Gabapentin | 79 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 71 | 19 |
| Levothyroxine Sodium | Levothyroxine Sodium | 67 | 20 |
| Trulicity | Dulaglutide | 57 | suppressed |
| Furosemide | Furosemide | 55 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | suppressed |
| Ozempic | Semaglutide | 53 | 13 |
| Omeprazole | Omeprazole | 52 | 17 |
| Carvedilol | Carvedilol | 48 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 11 |
| Famotidine | Famotidine | 48 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 12 |
| Metformin Hcl | Metformin Hcl | 45 | 14 |
| Jardiance | Empagliflozin | 41 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 41 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 40 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 12 |
| Spironolactone | Spironolactone | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | 13 |
| Prednisone | Prednisone | 36 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 12 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 31 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | 11 |
| Clonazepam | Clonazepam | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Eliquis | Apixaban | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | 13 |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Simvastatin | Simvastatin | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Ursodiol | Ursodiol | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Estradiol Valerate | Estradiol Valerate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $55.76 · 2 records | ViiV Healthcare Company | APRETUDE, Hillrom - ELI 280 | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error